U.S.
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  FORM 10-K  (Mark One) [X]
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 For
Fiscal Year Ended: December 31, 2009 OR [
 ]
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number:  333-144226 ARTVENTIVE MEDICAL GROUP, INC.(Exact name of registrant as specified in its
charter)Nevada

26-0148468(State or other jurisdiction of incorporation or
organization)

(IRS Employer Identification No.)1797 Playa VistaSan Marcos, CA

92078(Address of principal executive offices)

(Postal Code) Issuer's telephone number:
 (760) 471-7700 Securities registered under
Section 12(b) of the Act:  None Securities registered under
Section 12(g) of the Act:  None Indicate by check mark
if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the
Securities Act.  Yes [  ]  No  [x]  Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or 15(d) of the Exchange Act.  Yes [
 ]  No  [x] Indicate by check
mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.  Yes [x]
    No  [  ] Indicate by check mark whether the
registrant has submitted electronically and posted on its corporate Website, if
any, every Interactive Data File required to be submitted and posted pursuant to
Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required to submit
and post such files).  [  ] Yes  [X] No (Not required by smaller
reporting company)  Indicate by check
mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K
is not contained herein, and will not be contained, to the best of registrant's
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K.
 [  ] Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer,
or a smaller reporting company.  See the definitions of large accelerated
filer, accelerated filer, and smaller reporting company in Rule 12b-2 of
the Exchange Act.   (Check one): Large Accelerated Filer [  ] Accelerated Filer [  ] Non-Accelerated Filer [  ] Smaller reporting
company [X] (Do not check if a smaller reporting company)   Indicate by
check mark whether the registrant is a shell company (as defined in Rule 12b-2
of the Exchange Act). Yes  [  ]
   No [X] As of March 31,
2010 there were 43,027,066 shares of the registrant's common stock, par value
$0.001, issued and outstanding.  Of these, 21,430,200 shares are held by
non-affiliates of the registrant.  The market value of securities held by
non-affiliates is approximately $0.00 as our common stock does not presently
trade.  DOCUMENTS INCORPORATED BY REFERENCE  If the following documents are incorporated by reference,
briefly describe them and identify the part of the Form 10-K (e.g., Part I,
Part II, etc.) into which the document is incorporated:  (1) any
annual report to security holders; (2) any proxy or information statement;
and (3) any prospectus filed pursuant to Rule 424(b) or (c) of the
Securities Act of 1933, as amended (Securities Act).Not Applicable.        2    TABLE
OF CONTENTS Item
Number and Caption Page Cautionary
statements regarding forward-looking information 4 Description
of Business 4 ITEM
1A RISK
FACTORS 6 ITEM
1B UNRESOLVED
STAFF COMMENTS. 6 ITEM
2 PROPERTIES 6 ITEM
3 LEGAL
PROCEEDINGS. 6 PART
II 6 ITEM
5 MARKET
FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES
OF EQUITY SECURITIES.  6 ITEM
6 SELECTED
FINANCIAL DATA 7 ITEM
7 MANAGEMENTS
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.  7 ITEM
8 FINANCIAL
STATEMENTS AND SUPPLEMENTARY
DATA 8 ITEM
9 CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE  8 ITEM
9A [T] CONTROLS
AND PROCEDURES 8 ITEM
9B OTHER
INFORMATION 9 PART
III 9 ITEM
10 DIRECTORS,
EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE 9 ITEM
11 EXECUTIVE
COMPENSATION 12 ITEM
12 SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND   MANAGEMENT AND RELATED
STOCKHOLDER MATTERS  13 ITEM
13 CERTAIN
RELATIONSHIP AND RELATED TRANSACTIONS, AND   DIRECTOR
INDEPENDENCE  14 ITEM
14 PRINCIPAL
ACCOUNTANT FEES AND SERVICES 15 PART
IV 17 ITEM
15 EXHIBITS
AND FINANCIAL STATEMENT SCHEDULES 17 SIGNATURES 18        3   CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING
INFORMATION Except for historical information, this report contains
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934.  Such forward-looking statements involve risks and
uncertainties, including, among other things, statements regarding the Companys
business strategy, future revenues and anticipated costs and expenses.
 Such forward-looking statements include, among others, those statements
including the words expect, anticipate, intend, believe and similar
language.  The Companys actual results may differ significantly from those
projected in the forward-looking statements.  Factors that might cause or
contribute to such differences include, but are not limited to, those discussed
in the sections Plan of Operation and Business.  You are cautioned not
to place undue reliance on the forward-looking statements, which speak only as
of the date of this report.  We undertake no obligation to publicly release
any revisions to the forward-looking statements or reflect events or
circumstances taking place after the date of this document. Although we believe that the expectations reflected in these
forward-looking statements are based on reasonable assumptions, there are a
number of risks and uncertainties that could cause actual results to differ
materially from such forward-looking statements.  All
references depicted in this Form 10-K to the Company, ArtVentive, we, us
or our are to ArtVentive Medical Group, Inc.      Description of
Business  General Information  ArtVentive Medical Group, Inc. (the Company) was incorporated on
January 23, 2007, in the State of Nevada,as
Big Bear Resources, Inc.  Its name was changed to Uranium Plus Resource
Corporation on March 21, 2008.  It changed its name on January 26, 2010, to
ArtVentive Medical Group, Inc.  Its operations are primarily based in San
Marcos, California.  The accounting and
reporting policies of the Company conform to accounting principles generally
accepted in the United States of America, and the Companys fiscal year end is
December 31.  The
Company is a development stage company that was engaged primarily in the
acquisition, exploration and development of resource properties.  The
Company had previously negotiated an option to acquire a 100 percent interest in
a mineral claim located in the Slocan Mining Division in the Province of British
Columbia, Canada.  However, following extensive due diligence, the Company
elected not to proceed with the acquisition andabandoned all other interests in potential projects within the Province
of British Columbia, Canada.  Management entered into a consulting agreement with Dr. Allan P.
Juhas Ph.D., an Economic Geologist residing in the USA, with extensive
experience in international property evaluation and mineral exploration.
 Dr. Juhas and his team traveled to Peru and visited two of the Companys
proposed properties.  Although the deposits of commercial grade and size
occurred in the area, it was determined that any further work would require more
land to develop the potential resources in the area.  Following receipt of
the geological reports and sample analysis, management decided in 2009 not to
move forward with the further exploration of this property.  Dr.
Juhas and his team also evaluated another proposed acquisition, the El Zorro
gold prospect consisting of 600 hectares and located 156 kilometers north east
of Trujillo, Peru.  Following  4   receipt of the geological report from Dr. Juhas and subsequent
sample analysis, management also decided not to move forward with the further
exploration of this property.  The
Company no longer continues its expressed interest in the acquisition of a 1,000
hectare copper property north of Lima called the Corani.  The Company is no
longer continuing its discussions regarding a potential option to acquire an
additional uranium property calledCorongo.  On
January 8, 2010, the Company entered into an Asset Purchase Agreement with
ArtVentive, Inc., a California corporation.  Under the terms of the Asset
Purchase Agreement, ArtVentive, Inc. agreed to sell to the Company substantially
all of the assets of ArtVentive in exchange for 21,430,200 restricted shares of
the Companys common stock, which were issued equally to the shareholders of
ArtVentive, Inc.  Additionally, under the terms of the Agreement, the
Company changed its name to ArtVentive Madical Group, Inc. and effectuated a
forward split of the Companys issued common stock.  The stock split went
effective on February 16, 2010, however the Companys financial statements have
been retroactively restated to reflect the 1.65 forward split.  Following
the split, each shareholder will receive 1.65 new shares for each old share held
on that date, issued upon surrender of old shares.  Following the split and
the issuance of the shares under the Asset Purchase Agreement, there were
approximately 42,860,400 shares issued and outstanding.  Administration  The
Company is currently managed by Dr. Leon Rudakov, PhD, CEO, CTO and a member of
the Board of directors.  H. James Graham, the Companys prior CEO, serves
as Chairman of the Board.  Compliance with Government Regulation  As the
Company proceeds with its new programs involving medical devices and treatments,
it will have to comply with governmental regulations involving such activities.
 The type and extent of such regulation will be determined in 2010.  Employees  The
Company has no employees at this time, other than officers, as of the date of
this report.  Research and Development Expenditures  The
Company has not incurred any research or development expenditures since its
incorporation.  Subsidiaries   The
Company does not have any subsidiaries as of this filing.     5   **Patents and Trademarks**  The Company does not own, either legally or beneficially, any
patents or trademarks.   ITEM 1A RISK FACTORS  Not
Applicable.    ITEM 1B UNRESOLVED STAFF COMMENTS.  Not
Applicable.   ITEM 2 PROPERTIES  Effective January 26, 2010, the Companys corporate offices are
located at 1797 Playa Vista, San Marcos, California, 92078.  This space is
provided to the Company free of charge by its CEO.  The Company has no
other properties.   ITEM 3 LEGAL PROCEEDINGS.  Legal Proceedings  In the
ordinary course of business, the Company may, from time to time, become subject
to routine litigation or administrative proceedings which are incidental to the
business.  The Companyis not a party
to or aware of any existing, pending or threatened lawsuits or other legal
actions involving the Company.        PART
II   ITEM 5 MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.  Market Information  Bid
and ask prices for the Companys common stock have been quoted on the
Over-The-Counter Bulletin Board (the OTCBB) under the symbol AVTD.OB since
April 3, 2008. However, the Companys stock has never traded.  As of
March 31, 2010, the Company had 35 shareholders of record.  Dividends  The
Company has never declared any cash dividends with respect to its common stock.
 Future payment of dividends is within the discretion of theboard of directors and will depend on the
Companys earnings, capital requirements, financial condition and other relevant
factors.  Although there are no material restrictions limiting, or that are
likely to limit, the Companys  6   ability to pay dividends on its common stock, it presently intends
to retain future earnings, if any, for use in its business and currently has no
intention to offer cash dividends on itscommon stock.  Recent Sales of Unregistered Securities  During
the fiscal year ended December 31, 2009, the Company did not issue any
securities without registration under the Securities Act of 1933.   ITEM 6 SELECTED FINANCIAL DATA  Not
applicable.   ITEM 7 MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.  Results of Operations  The
Company has not generated revenues sinceits
inception on January 23, 2007, and has an
accumulated deficit of $204,523 from inception to December 31, 2009. (See Note 5
of the Notes to Financial Statements included herewith.)  The
following table provides selected financial data about the Company as of and for
the year ended December 31, 2009.  Balance Sheet Data:



December 31, 2009



December 31, 2008Cash


$
60,791


$
93,139Total assets


$
60,791


$
93,139Total liabilities


$
154,411


$
158,124Stockholders' Equity/(Deficit)


$
(93,620)


$
(64,985)    Plan
of Operation  ArtVentive Medical Group, Inc. (ArtVentive or the Company), is
a Nevada Corporation trading on the OTC-BB (symbol AVTD).  On March 21,
2008, the Company changed its name from Big Bear Resources Inc. to Uranium Plus
Resource Corporation.  On January 26, 2010, the Company changed its name to
ArtVentive Medical Group, Inc.  Prior
to March 2008, the Company had acquired options to potentially mine properties
in British Columbia and Peru.  However, with the acquisition of the assets
of ArtVentive, Inc., as described below, the Company does not expect to continue
with the potential mining activities for the foreseeable future.    7   On January 8, 2010, the Company entered into an Asset Purchase
Agreement with ArtVentive, Inc., a California corporation.  Under the terms
of the Agreement, ArtVentive, Inc. agreed to sell to the Company substantially
all of the assets of ArtVentive in exchange for shares of the Companys common
stock.  The Asset Purchase Agreement was filed as an exhibit to our Current
Report on Form 8-K on January 11, 2010.  Pursuant to the terms of the
Agreement, the Company filed a Certificate of Amendment changing its name to
ArtVentive Medical Group, Inc.  Additionally, it authorized a forward split
of the issued shares of its common stock on a ratio of 1.65 new shares for 1 old
share.  This forward split was declared effective by FINRA on February 16,
2010.  On February 26, 2010, the Company issued 21,430,200 shares to the
two shareholders of ArtVentive, Inc.  To
date, the Companys activities have been limited to its formation, minimal
operations, the raising of equity capital and exploring other international
business opportunities.  Limited Operating History  There
is no historical financial information about the Company upon which to base an
evaluation of its performance.  The Company is a development stage
corporation and has not generated any revenues from its business operations.
 The Company cannot guarantee that it will be successful in its business
operations.  The Companys business is subject to risks inherent in the
establishment of a new business enterprise, including limited capital resources
and possible cost overruns due to price and cost increases in services and
products.  The
Company gives no assurance that future financing will be available on acceptable
terms.  If financing is not available on such terms, the Company may be
unable to continue, develop or expand its operations.  Additionally, equity
financing could result in additional dilution to existing shareholders.  Liquidity and Capital Resources  As of
the date of this report, the Company has yet to generate any revenues from its
business operations.  Since inception the Companys main source of cash has
been the sale of its equity securities.  As of
the date of this filing, the Company has yet to begin operations and therefore
has not generated any revenues.  As of
December 31, 2009, cash and total assets were $60,791 and the Companys total
liabilities were $154,411.  (See 5 of the Notes to Financial Statements
included herewith.)   ITEM
8  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA   8


ArtVentive Medical Group Inc. (Formerly Uranium Plus Resource Corporation) A Development Stage Company Financial Statements For the Period from January 23, 2007 (Inception) to December 31,
2009                Balance
Sheets as of December 31, 2009 and December 31, 2008 Statement
1  Statements of
Operations and Comprehensive Loss for the years ended December 31, 2009 and December 31,
2008; and
the period from inception (January 23, 2007) through December 31, 2009 Statement
2  Statements of Cash
Flows for the years ended December 31, 2009 and December 31,
2008; and
for the period from January 23, 2007 (Inception) to December 31, 2009 Statement
3  Statements of Changes
in Stockholders Equity (Deficit) for the period from January
23, 2007 (Inception) to December 31, 2009 Statement
4  Notes to Financial
Statements


9


[atvdform10k123109v5final002.gif]  Statement 1 ArtVentive
Medical Group Inc. (Formerly
Uranium Plus Resource Corporation) A
Development Stage Company Balance Sheets December
31, 2009 and December 31, 2008   ASSETS
December 31
December 312009
2008CURRENTCash
and cash equivalents
$
60,791
$
93,139TOTAL
CURRENT ASSETS
60,791
93,139TOTAL
ASSETS
$
60,791
$
93,139LIABILITIES AND STOCKHOLDERS DEFICITCURRENTAccounts
payable
$
4,411
$
8,124Convertible
note payable (Note 5)
150,000
150,000TOTAL
LIABILITIES
154,411
158,124STOCKHOLDERS
DEFICITCommon
stock, par value $.001, 100,000,000 sharesauthorized,
21,430,200 shares issued and outstanding after
giving
effect to 1.65 for 1 split on February 16, 2010
21,430
21,430Additional
paid in capital
89,473
89,473Deficit
accumulated during the development stage
(204,523)
(176,268)Accumulated
other comprehensive income

380TOTAL
STOCKHOLDERS DEFICIT
(93,620)
(64,985)TOTAL
LIABILITIES AND STOCKHOLDERS DEFICIT
$
60,791
$
93,139  (See
accompanying notes)


Statement 2 ArtVentive
Medical Group Inc. (Formerly
Uranium Plus Resource Corporation) A
Development Stage Company Statements of
Operations and Comprehensive Loss For
the Years Ended December 31, 2009 and December 31, 2008; and the Period from
Inception (January 23, 2007) through December 31, 2009;   For the year ended December 31, 2009
For the year ended
December 31, 2008
For the period  from January 23, 2007 (Inception) to
December 31, 2009REVENUES
$
NIL
$
NIL
$
NILOPERATING
EXPENSESExploration
costs
--
20,533
45,533Selling,
general and administrative
28,255
64,242
156,474Depreciation
expense
--
102
516OPERATING
LOSS BEFORE OTHER ITEMS AND INCOME TAX
(28,255)
(84,877)
(204,523)Income
tax expense (benefit)
--
--
--NET
LOSS AVAILABLE TO COMMON STOCKHOLDERS
(28,255)
(84,877)
(204,523)OTHER
COMPREHENSIVE INCOMEForeign
currency translation adjustment
(380)
(75)
-COMPREHENSIVE
LOSS FOR THE PERIOD
$
(28,635)
$
(84,952)
$
(204,523)BASIC
AND DILUTED LOSS PER COMMON SHARE
(0.00)
(0.00)WEIGHTED
AVERAGE SHARES OUTSTANDING
21,430,200
21,430,200 Statement 3 ArtVentive
Medical Group Inc. (Formerly
Uranium Plus Resource Corporation) A
Development Stage Company Statements of Cash
Flows For
the Year Ended December 31, 2009 and December 31, 2008; and for the Period from
January 23, 2007 (Inception) to December 31, 2009   For the year ended December 31, 2009
For the year ended
December 31, 2008
For the period  from January 23, 2007 (Inception) to
December 31, 2009CASH
FLOW FROM OPERATING ACTIVITIESNet
loss
$
(28,255)
$
(84,877)
$
(204,523)ADJUSTMENTS TO
RECONCILE NET LOSS TO NET CASH USED BY OPERATING ACTIVITIESNon-cash
expenses
--
8,621
60,805Depreciation
expense
--
102
516CHANGES
IN OPERATING ASSETS AND LIABILITIESPrepaid
expenses
--
1,224
-Accounts
payable
(3,713)
6,820
4,411Accounts
payable  related party
--
9,000
39,000NET
CASH USED BY OPERATING ACTIVITIES
(31,968)
(59,110)
(99,791)CASH
FLOWS FROM INVESTING ACTIVITIESDisposal
of equipment
--
745
745Purchase
of equipment
--

(1,243)NET
CASH PROVIDED (USED) BY INVESTING ACTIVITIES
--
745
(498)CASH
FLOWS FROM FINANCING ACTIVITIESIssuance
of common stock for cash
--
--
11,080Convertible
note payable (see Note 5)
--
150,000
150,000NET
CASH PROVIDED, BY FINANCING ACTIVITIES
--
150,000
161,080NET
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
(31,968)
91,635
60,791EFFECT
OF EXCHANGE RATE CHANGES ON CASH
(380)
(75)
--CASH,
BEGINNING OF PERIOD
93,139
1,579
-CASH,
END OF PERIOD
$
60,791
$
93,139
$
60,791 NON-CASH
INVESTING AND FINANCING ACTIVITIES FORGIVENESS OF
RELATED PARTY NOTE; APPLIED TO PAID IN CAPITAL
$
$
39,000
$
39,000


Statement 4 ArtVentive
Medical Group Inc. (Formerly
Uranium Plus Resource Corporation) A
Development Stage Company Statement of
Changes in Stockholders Deficit From
Inception, January 23 2007, to December 31 2009   Common
Share
Additional Paid in
Deficit Accumulated
Accumulated Other Comprehensive
Total EquityShares
Amount
For period
DuringPeriod
Income
(Deficit)BALANCE,
JANUARY 23, 2007
-
$
-
$
-
$
-
$
-
$
-Common
shares issued for cash, assets and expenses at $.00075 per share
21,430,200
21,430
(5,350)
-
-
16,080Capital
contribution of Expenses


47,184
-
-
47,184Loss
during the period from Inception toDecember 31,
2007


-
(91,391)
-
(91,391)Foreign
currency translation adjustments


-
-
455
455BALANCE,
DECEMBER 31, 2007
21,430,200
21,430
41,834
(91,391)
455
(27,672)Capital
Contribution of Expenses
-
-
47,639
-
-
47,639Loss
during the year (2008)
-
-
-
(84,877)
-
(84,877)Foreign
currency translation adjustments
-
-
-
-
(75)
(75)BALANCE
DECEMBER 31, 2008
21,430,000
21,430
89,473
(176,268)
380
(64,985)Foreign
currency translation adjustments




(380)
(380)Loss
during year (2009)



(28,255)

(28,255)BALANCE
DECEMBER 31, 2009
21,430,000
$
21,430
$
89,473
$
(204,523)
$
0
$
(93,620)


(See
accompanying notes)


ArtVentive
Medical Group Inc. (Formerly
Uranium Plus Resource Corporation) A
Development Stage Company Notes to Financial
Statements For
the Year Ended December 31, 2009  1. BASIS
OF FINANCIAL STATEMENT PRESENTATION  The
accompanying audited financial statements have been prepared by the Company
pursuant to the rules and regulations of the Securities and Exchange
Commission.  The
information furnished in the financial statements includes normal recurring
adjustments and reflects all adjustments which in the opinion of management are
necessary for a fair presentation of such financial statements.  2. ORGANIZATION Uranium
Plus Resource Corporation (the Company) was incorporated on January 23, 2007
in the State of Nevada, U.S.A., as Big Bear Resources, Inc.  Its name was
changed to Uranium Plus Resource Corporation on March 21, 2008.  On January
26, 2010, its name was change to Artventive Medical Group, Inc.  During
2009, its operations were primarily based in Mill Creek, Washington, USA.
 The accounting and reporting policies of the Company conform to accounting
principles generally accepted in the United States of America, and the Companys
fiscal year end is December 31.  The
Company, as an exploration stage company, was engaged in the acquisition,
exploration and development of resources properties.  Previously acquired
mineral claims in British Columbia, Canada and exploration on mineral claims in
Peru have been terminated.  More recently, the Companys activities have
been focused on maintaining operations, raising equity capital and exploring
other business opportunities.  The Company has recently entered into
agreements that move the operations from the exploration stage to the
development stage (see Note 10).  3. SIGNIFICANT
ACCOUNTING POLICIES USE
OF ESTIMATES  The preparation of the Companys financial statements in
conformity with accounting principles generally accepted in the United States
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amount of
revenues and expenses during the reporting period.  Actual results could
differ from those estimates.  The Companys periodic filings with the
Securities and Exchange Commission include, where applicable, disclosures of
estimates, assumptions, uncertainties and markets that could affect the
financial statements and future operations of the Company.      ArtVentive
Medical Group Inc. (Formerly
Uranium Plus Resource Corporation) A
Developpment Stage Company Notes to Financial
Statements For
the Year Ended December 31, 2009  FOREIGN
CURRENCY TRANSLATIONS The Companys functional and reporting currency is the US dollar.
 All transactions initiated in other currencies are translated into US
dollars using the exchange rate prevailing on the date of transaction.
 Monetary assets and liabilities denominated in foreign currencies are
translated into the US dollar at the rate of exchange in effect at the balance
sheet date.  Unrealized exchange gains and losses arising from such
transactions are deferred until realization and are included as a separate
component of stockholders equity (deficit) as a component of other
comprehensive income or loss. Upon realization, the amount deferred is
recognized in income in the period when it is realized.  The Company recorded an unrealized foreign currency translation
gain, totaling $0 for the period from January 23, 2007 (Inception) to December
31, 2009, in accumulated other comprehensive income.  Cash and Cash equivalents Cash and cash equivalents consist of funds on deposit with banks.
 The Company has no cash equivalents.  The Company had funds on
deposit of $60,791 as at December 31, 2009.  4. RELATED
PARTY TRANSACTIONS A $3,000 per month salary to the President of the Company was
accrued up through March 21, 2008 and was subsequently forgiven on May 4, 2008.
 The related expense was charged to selling, general and administrative
expenses; $30,000 through December 31, 2007 and an additional $9,000 to March
31, 2008.  The forgiveness of debt has been recorded as an increase in
additional paid in capital as of December 31, 2008.  5. CONVERTIBLE
NOTE PAYABLE   The Company borrowed $150,000 pursuant to an agreement dated April
29, 2008.  The loan is payable on demand by the Lender.  The Lender
has the option to convert the loan into common shares of the company at a rate
of 1 common share for each $1 borrowed (150,000 common shares).  In
the event repayment is demanded and the Company defaults, interest at a rate of
8% per annum shall be charged from the date of demand.  All
funds are in US dollars.  See also  Note 10  6. SHARE
CAPITAL Effective April 22, 2008, the Company forward-split its issued
capital stock on a ratio of 5.8 shares for each one old share.  As a result
of this transaction, 11,078,000 shares were issued.  Effective February 12,
2010, the Company forward-split its issued capital stock on a ratio of 1.65
shares for each one old share.  As a result of this transaction, 8,442,200
shares were issued. Shares
ValueDecember 31, 2008
1,910,000
$
1,910Issued as a result of forward-split 4/22/08
11,078,000
11,078Issued as a result of forward-split 2/12/10
8,442,200
$
8,442December 31, 2008 and
2009
21,430,200
$
21,430  Consideration
for the issue of additional shares has been charged against additional paid in
capital. The
adjustment has been reflected retroactively.


ArtVentive
Medical Group Inc. (Formerly
Uranium Plus Resource Corporation) A
Development Stage Company Notes to Financial
Statements For
the Year Ended December 31, 2009  7. GOING
CONCERN AND LIQUIDITY CONSIDERATIONS The accompanying financial statements have been prepared assuming
that the Company will continue as a going concern, which contemplates, among
other things, the realization of assets and satisfaction of liabilities in the
normal course of business.  As of December 31, 2009, the Company has a
negative working capital balance of $93,620 and an accumulated deficit of
$204,523.  The Company intends to fund operations through equity financing
arrangements, which may be insufficient to fund its capital expenditures,
working capital and other cash requirements for the next twelve months.  The
ability of the Company to emerge from the development stage is dependent upon,
among other things, obtaining additional financing to continue operations,
explore and develop the mineral properties and the discovery, development and
sale of mineral reserves.  In
response to these challenges, management intends to raise additional funds
through public or private placement offerings.  These
factors, among others, raise substantial doubt about the Companys ability to
continue as a going concern.  The accompanying financial statements do not
include any adjustments that might result from the outcome of this
uncertainty.  8. RECENTLY
ISSUED ACCOUNTING PRONOUNCEMENTS  In June 2009, the FASB established the Accounting Standards
Codification (Codification or ASC) as the source of authoritative accounting
principles recognized by the FASB to be applied by nongovernmental entities in
the preparation of financial statements in accordance with generally accepted
accounting principles in the United States (GAAP).  Rules and
interpretive releases of the Securities and Exchange Commission (SEC) issued
under authority of federal securities laws are also sources of GAAP for SEC
registrants.  Existing GAAP was not intended to be changed as a result of
the Codification, and accordingly the change did not impact our financial
statements.  The ASC does change the way the guidance is organized and
presented.  Statement of Financial Accounting Standards (SFAS) SFAS No. 166
(ASC Topic 810), Accounting for Transfers of Financial Assetsan Amendment of
FASB Statement No. 140, SFAS No. 167 (ASC Topic 810), Amendments to FASB
Interpretation No. 46(R), and SFAS No. 168 (ASC Topic 105), The FASB
Accounting Standards Codification and the Hierarchy of Generally Accepted
Accounting Principlesa replacement of FASB Statement No. 162 were recently
issued.  SFAS No. 166, 167, and 168 have no current applicability to the
Company or their effect on the financial statements would not have been
significant.  Accounting Standards Update (ASU) ASU No. 2009-05 (ASC Topic
820), which amends Fair Value Measurements and Disclosures  Overall, ASU No.
2009-13 (ASC Topic 605), Multiple-Deliverable Revenue Arrangements, ASU No.
2009-14 (ASC Topic 985), Certain Revenue Arrangements that include Software
Elements, and various other ASUs No. 2009-2 through ASU No. 2010-11 which
contain technical corrections to existing guidance or affect guidance to
specialized industries or entities were recently issued.  These updates
have no current applicability to the Company or their effect on the financial
statements would not have been significant.      ArtVentive
Medical Group Inc. (Formerly
Uranium Plus Resource Corporation) A
Development Stage Company Notes to Financial
Statements For
the Year Ended December 31, 2009  9. PROVISION
FOR INCOME TAXES The Company recognizes the tax effects of transactions in the year
in which such transactions enter into the determination of net income,
regardless of when reported for tax purposes.  Deferred taxes are provided
in the financial statements under ASC Topic 740 to give effect to the resulting
temporary differences which may arise from differences in the bases of fixed
assets, depreciation methods, allowances, and start-up costs based on the income
taxes expected to be payable in future years. Minimal exploration stage deferred
tax assets arising as a result of net operating loss carryforwards have been
offset completely by a valuation allowance due to the uncertainty of their
utilization in future periods.  Operating loss carryforwards generated
during the period from January 23, 2007 (date of inception) through December 31,
2009 of approximately $204,523 will begin to expire in 2028. Accordingly,
deferred tax assets of $69,538 (2008  $59,931) were offset by the valuation
allowance in the same amount. The Company adopted the provisions of ASC Topic 740 Accounting for
Uncertainty in Income Taxes, on January 1, 2007.  As a result of the
implementation of Interpretation 48, the Company recognized no increase in the
liability for unrecognized tax benefits. The Company has no tax positions at December 31, 2009 and 2008 for
which the ultimate deductibility is highly certain but for which there is
uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized
tax benefits in interest expense and penalties in operating expenses.
 During the years ended December 31, 2009, 2008 and 2007, the Company
recognized no interest and penalties.  The Company had no accruals for
interest and penalties at December 31, 2009, 2008 and 2007. Components
of income tax are as follows: Years Ended December 312009

2008Current

$
-

$
-Federal

-

-State

-

--

-Deferred

-

-$
-

$
-  A
reconciliation of the provision for income tax expense with the expected income
tax computed by applying the federal statutory income tax to income before
provision for income taxes is as follows:  Years  Ended December 312009

2008Income tax
computed atFederal
statutory tax rate of 34%
$
(9,607)

$
(28,833)State taxes
(net of federal benefit)
-

-Valuation
Allowance
9,607

28,833$
-

$
-     ArtVentive
Medical Group Inc. (Formerly
Uranium Plus Resource Corporation) A
Develo9pment Stage Company Notes to Financial
Statements For
the Year Ended December 31, 2009   10. SUBSEQUENT
EVENTS  Effective
September 25, 2009, the Company implemented a new ASC accounting
pronouncement,Subsequent Events. This standard establishes
general standards of accounting for and disclosure of events that occur after
the balance sheet date but before financial statements are issued. The adoption
of this accounting pronouncement did not impact our financial position or
results of operations. The Company evaluated all events or transactions that
occurred after December 31, 2009 up through the date these financial statements
were issued. During this period the Company had the following material
recognizable subsequent events.  (i) On
January 8, 2010, the Company entered into an Asset Purchase Agreement with
ArtVentive, Inc., a California corporation.  Under the terms of the Asset
Purchase Agreement, ArtVentive, Inc. agreed to sell to the Company substantially
all of the assets of ArtVentive in exchange for 21,430,200 restricted shares of
the Companys common stock, which were issued equally to the shareholders of
ArtVentive, Inc. (ii) On
February 5, 2010, the company changed its name to Artventive Medical Group,
Inc.  (iii) The holder of the convertible note (Note 5) has elected to convert
the note into common shares of the company. On February 22, 2010, the holder
executed a subscription agreement for 166,666 common shares at $.90 per share as
consideration for converting the note.  (iv) On January 22, 2010, the Board of Directors and a majority of
shareholders approved a forward split of the Companys common stock on a ratio
of 1.65 new shares for each old share held.  The split took effect on
February 12, 2010, resulting in an increase in issued and outstanding common
shares from 12,988,000 to approximately 22,430,200.


ITEM 9 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE  Not
applicable.   ITEM 9A [T] CONTROLS AND PROCEDURES  Evaluation of Our Disclosure Controls and Internal
Controls  Under
the supervision and with the participation of senior management, including the
Companys President and principal financial officer, Jim Graham, the management
conducted an evaluation of the effectiveness of the design and operation of the
Companys  disclosure controls and procedures, as defined in Rules
13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended
(the Exchange Act), as of the end of the period covered by this annual report
(the Evaluation Date).  Based on this evaluation, the President and
Principal Financial Officer concluded as of the Evaluation Date that the
disclosure controls and procedures were effective such that the information
relating to the Company  including its  consolidated subsidiaries,
required to be disclosed in its  Securities and Exchange Commission (SEC)
reports (i) is recorded, processed, summarized and reported within the time
periods specified in SEC rules and forms, and (ii) is accumulated and
communicated to management, including the President and Principal Financial
Officer, as appropriate to allow timely decisions regarding required disclosure.  Managements Annual Report on Internal Control over Financial
Reporting  The
management of the Company is responsible for establishing and maintaining
adequate internal control over financial reporting.  The internal control
process has been designed, under managements supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation
of the Companys financial statements for external reporting purposes in
accordance with accounting principles generally accepted in the United States of
America.  Management conducted an assessment of the effectiveness of the
Companys internal control over financial reporting as of December 31, 2009,
including (i) the control environment, (ii) risk assessment, (iii) control
activities, (iv) information and communication, and (v) monitoring.  Based
on this assessment, management has determined that the Companys internal
control over financial reporting as of December 31, 2009 was effective.  The
Companys internal control over financial reporting is a process designed to
provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance
with accounting principles generally accepted in the United States.
 Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements.  Therefore, even those
systems determined to be effective can provide only reasonable assurance of
achieving their control objectives.  In evaluating the effectiveness of the
Companys internal control over financial reporting, management used the
criteria set forth by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO) in Internal Control  Integrated Framework.





This annual report does not include an attestation report of the
Companys registered public accounting firm regarding internal control over
financial reporting.  Managements report was not subject to attestation by
its registered public accounting firm pursuant to temporary rules of the
Securities and Exchange Commission that permit the Company to provide only
managements report in this annual report.  Officers Certifications  Appearing as exhibits to this Annual Report are Certifications
of the Companys Chief Executive Officer and Principal Financial Officer.
 The Certifications are required pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 (the Section 302 Certifications).  This
section of the Annual Report contains information concerning the Controls
Evaluation referred to in the Section 302 Certification.  This information
should be read in conjunction with the Section 302 Certifications for a more
complete understanding of the topics presented.  Changes in Internal Control over Financial Reporting  There
have been no changes in the Companys internal control over financial reporting
that occurred during the quarter ended December 31, 2009 that have materially
affected or are reasonably likely to materially affect theinternal control over financial reporting.   ITEM 9B OTHER INFORMATION  Not
applicable.       PART
III   ITEM 10 DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE  Executive Officers, Directors and Key Employees  Directors serve until the next annual meeting of the stockholders;
until their successors are elected or appointed and qualified, or until their
prior resignation or removal.  Officers serve for such terms as determined
by the board of directors.  Each officer holds office until such officers
successor is elected or appointed and qualified or until such officers earlier
resignation or removal.  The
following table sets forth certain information, as of February 16, 2010, with
respect to the directors and executive officers.  Name
Positions Held
AgeH. James Graham
President, Chairman
59Leon Rudakov
CEO, CTO, Director
58





Mr. Graham has held the positions of CEO and director since April
28, 2008.  He resigned as CEO on February 11, 2010, as CEO, but agreed to
continue on as Chairman of the Board.  Dr. Rudakov was appointed as CEO and
CTO, and as a member of the Board of Directors on February 11, 2010.  Certain
biographical information of our directors and officers is set forth below.  H. James Graham has acted as President and CEO of a
number of successful corporations including start-up companies. Since 2006, Mr.
Graham has also developed global business plans and marketing strategies in
addition to drafting and negotiating international management and distribution
agreements. In 2000, Mr. Graham co-founded
CyberBroadcastOne Inc., an interactive broadcast company based on the foundation
of education, entertainment and commerce.  Mr. Graham served as the
President and CEO through 2006.  From 1993 to 2007, he served as a member
of the Board of Directors of Kodiak Oil and Gas, an emerging oil and gas company
with its head office in Denver, Colorado and operations throughout America.
 The Companys shares were traded on the Venture Stock Exchange (TSX) until
2007 and are now listed on the American Stock Exchange (AMX) under the symbol
KOG.  In 1998, Mr. Graham co-founded Pyrotech International Ltd.,
Singapore, a corporation committed to the development of a revolutionary fire
fighting gel recognized globally under the brand name Barricade.  Mr.
Graham served as CEO from 1998 to 2000.  Previously, Mr. Graham co-founded and was the President of
Tri-Pacific Resources Corporation, Hong Kong, a technology based corporation
specializing in onboard power supply and energy management systems.  He
also served as President of Hunter Douglas Canada, Inc., the worlds largest
vertically integrated supplier of aluminum and home fashions products to the
international market.  Hunter Douglas acquired the HJ Graham Company Ltd.
in 1989 which was previously founded and headed by Mr. Graham until the
acquisition.  Mr. Graham also served on the Board of Directors of Bradbury
International, Ltd., a diversified Canadian financial investment corporation,
trading on the Vancouver Stock, Exchange.  Dr. Leon Rudakov has more than 25 years experience
in R&D, engineering, product development and project management. He holds a
Ph.D. in mechanical engineering from the Moscow Institute of Aviation, and
completed Business Executive Program at the Fuqua Business School of the Duke
University, NC. He held several executive management and R&D positions with
international corporations and start-up companies.  In 2003
Dr. Rudakov joined Merlin Medical, a Singapore-based company, where he held the
position of vice-president of Research and Development and chief technology
officer. He was responsible for the company's business strategy, and directed
its product development and regulatory pathway. Under his leadership the Company
developed a new, unique intracranial device for the treatment of intracranial
aneurysms with significant potential for the treatment of ischemic disease. He
also established the Company intellectual property and led the device
development from the initial concept formulation to its production and the
clinical studies in several European Union countries. Dr. Rudakov also developed
the coronary stent "X'Calibur" and its delivery catheter through to its CE Mark
approval and current market presence in Asia.





Dr. Rudakov also served as a Director of Engineering with the
Silicon Valley corporation CardioVasc Inc., and led a cross functional group of
engineers through the production of several coronary devices, from development
to commercial success. Among these CardioVasc projects, Dr. Rudakov led the
development of a new coronary stent and delivery system, which was subsequently
sold to the Japanese corporation "Goodman Co". He also participated in the
device regulatory process leading to its approval in Japan.  Additionally, Dr Rudakov, managed development of a coated
stent-graft, for the treatment of failing saphenous vein graft (SVG). This
device has received CE Mark and is marketed and sold in the EU by the CardioVasc
Corporation.  Dr.
Rudakov has served as a Regional Director of Operations for Booz Allen &
Hamilton, a worldwide leader in management consulting. He managed the company's
operations and regional business development, while working with key corporate
clients, providing strategic business planning, corporate restructuring and
re-engineering.  In
2009, Dr. Rudakov joined ArtVentive, Inc., of San Marcos, California, as Chief
Executive Officer and Chief Technology Officer.  Term
of Office  Companydirectors are elected
for one-year terms, to hold office until the next annual general meeting of the
shareholders, or until removed from office in accordance with thebylaws of the Company.  Officers are
appointed by the board of directors and hold office until removed by the
board.  Significant Employees  The
Company has no significant employees other than the officers and directors
described above.  Employment Agreements  On
February 2, 2010, the Company entered into an Employment Agreement with its
Chief Executive Officer and Chief Technology Officer, Dr. Leon Rudakov.
 Under the terms of the Agreement, Dr. Rudakov will be compensated with an
annual salary of $120,000, plus benefits, including options to purchase stock in
the Company, the terms of which are to be negotiated, but the share price will
be the trading price at the time of issuance or the net book value.  Any
options granted will expire five years after the date of the grant.  The
term of the Employment Agreement will be for a period of five years, unless
earlier terminated under the terms of the Employment Agreement.  Audit Committee  The
Company does not currently have a standing audit committee, an audit committee
financial expert, or any committee or person performing a similar function.
 The Corporation haslimited working
capital and no revenues.  Management does not believe that it would be in
the best interest ofthe Company, at this time to retain independent directors to
sit on an audit committee.





When appropriate, the Company will retain independent directors
and form an audit, compensation committee and other applicable committees.  Board of Directors  The
Company does not have an independent director at this time.  Directors are
reimbursed for expenses, if any, for attendance at meetings of the Board of
Directors.  TheBoard of Directors may
designate from among its members an executive committee and one or more other
committees but has not done so to date.  The Company does not have a
nominating committee or a nominating committee charter.  Further, the
Company does not have a policy with regard to the consideration of any director
candidates recommended by security holders.  To date this has not been a
problem as no security holders have made any such recommendations.
 Directors perform all functions that would otherwise be performed by
committees.  Given the present size of theboard it is not practical forthe
Company to have such committees.  The Company plans to expand the Board of
Directors at the first opportunity    Compliance with Section 16(a) of the Exchange Act  The
Companys common stock is not registered pursuant to Section 12 of the
Securities Exchange Act of 1934, as amended (the Exchange Act).
 Accordingly, officers, directors and principal shareholders are not
subject to the beneficial ownership reporting requirements of Section 16(a) of
the Exchange Act.  Code
of Ethics  As of
December 31, 2009, the Company has not yet adopted a Code of Ethics.   ITEM 11 EXECUTIVE COMPENSATION  (a) No
officer or director of the Company received compensation during the past three
fiscal years.  (b)
There are no annuity, pension or retirement benefits proposed to be paid to
officers, directors, or employees of the corporation in the event of retirement
at normal retirement date pursuant to any presently existing plan provided or
contributed to by the corporation or any of its subsidiaries.  Director Compensation Members
of the Companys Board of Directors do not receive compensation, as such, at
this time, but are paid consulting fees for specific services as incurred.  Stock Option Grants  As of
the date of this Report, the Company has not granted any stock options.





Employment Agreements  On
February 2, 2010, the Company entered into an Employment Agreement with its
Chief Executive Officer and Chief Technology Officer, Dr. Leon Rudakov.
 Under the terms of the Agreement, Dr. Rudakov will be compensated with an
annual salary of $120,000, plus benefits, including options to purchase stock in
the Company, the terms of which are to be negotiated, but the share price will
be the trading price at the time of issuance or the net book value.  Any
options granted will expire five years after the date of the grant.  The
term of the Employment Agreement will be for a period of five years, unless
earlier terminated under the terms of the Employment Agreement.  Indemnification  Under
thebylaws of the Company, it may indemnify
an officer or director who is made a party to any proceeding, including a
lawsuit, because of his position, if he acted in good faith and in a manner he
reasonably believed to be in the Companys best interest.  The Company may
advance expenses incurred in defending a proceeding.  To the extent that
the officer or director is successful on the merits in a proceeding as to which
he is to be indemnified, we must indemnify him against all expenses incurred,
including attorneys fees.  With respect to a derivative action, indemnity
may be made only for expenses actually and reasonably incurred in defending the
proceeding, and if the officer or director is judged liable, only by a court
order.  The indemnification is intended to be to the fullest extent
permitted by the laws of the State of Nevada.  Regarding indemnification for liabilities arising under the
Securities Act, which may be permitted to directors or officers under Nevada
law, the Company is informed that, in the opinion of the Securities and Exchange
Commission, indemnification is against public policy, as expressed in the Act
and is, therefore, unenforceable.   ITEM 12 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS ANDMANAGEMENT AND RELATED STOCKHOLDER MATTERS  The
following table sets forth, as of December 31, 2009, the beneficial ownership of
the Companys common stock by each of itsofficers and directors, by each person known by the Company to
beneficially own more than 5% of  common stock and by  officers and
directors as a group.  Except as otherwise indicated, all shares are owned
directly and the percentage shown is based on 12,988,000 shares of common stock
issued and outstanding on December 31, 2009.





Name and
Address of Beneficial Owner
Number of
Shares of Common Stock
Percentage
Ownership of Common StockEstate of Scott
Houghton
1525 Yew
Street
Vancouver,
B.C.
Canada, V6J
3E5
5,880,000
(*9,702,000)
45.3%Korina
Houghton
804  1238
Melville Street
Vancouver,
BC
Canada V6E
4N2
2,900,000
(*4,785,000)
22.3%James
Graham
Suite 107 
17624 15th Ave.
Mill Creek, WA
98012
President,
Chairman
0
0%Dr. Leon
Rudakov
1797 Playa
Vista
San Marcos, CA
92078
CEO, CTO,
Director
0
(**10,715,100)
0Officers and
Directors as a Group (2)
0
0% *On February 16, 2010, the Company effectuated a 1.65
for 1 forward split of its common stock.  Outstanding shares as of that
date increased to approximately 21,430,200.  The post-split number of
shares for each shareholder is listed in parenthesis.  Percentage ownership
did not change. **
On February 11, 2010, Dr. Leon Rudakov was appointed to the Board of Directors
of the Company.  On February 26, 2010, he was issued 10,715,100 shares.  Securities Authorized
for Issuance under Equity Compensation Plans  The Company has not
adopted any equity compensation plans since our inception.   ITEM
13 CERTAIN
RELATIONSHIP AND RELATED TRANSACTIONS, ANDDIRECTOR INDEPENDENCE  Other
than as set forth in this section, none of the following parties has, since
thedate of incorporation, any material
interest, direct or indirect, in any transaction with the Company or in any
presently proposed transaction that has or will materially affect the
Company:  *
   Director or Officer; *
   Any person proposed as a nominee for election as a
director;





*   Any person who beneficially owns, directly or
indirectly, shares carrying more than 10% of the voting rights attached to our
outstanding shares of common stock; *
   Any promoters; *   Any relative or spouse of any of the foregoing
persons who has the same house as such   person.      ITEM
14 PRINCIPAL
ACCOUNTANT FEES AND SERVICES  Audit
Fees  The aggregate fees
billed to the Company by itsprincipal
accountant for services rendered during the fiscal year ended December 31, 2009
and 2008 is set forth in the table below:  Fee
Category

Fiscal year
ended December 31, 2009

Fiscal year
ended
December 31,
2008Audit fees
(1)

$11,000

$11,000Audit-related
fees (2)

0

0Tax fees
(3)

0

0All other fees
(4)

0

0Total
fees

$11,000

$11,000  (1)
Audit fees consist of fees incurred for professional services rendered for the
audit of our financial statements, for reviews of the  interim financial
statements included in the Companys quarterly reports on Form 10-Q and for
services that are normally provided in connection with statutory or regulatory
filings or engagements.  (2)
Audit-related fees consist of fees billed for professional services that are
reasonably related to the performance of the audit or review of the Companys
consolidated financial statements, but are not reported under Audit fees.  (3) Tax
fees consist of fees billed for professional services relating to tax
compliance, tax planning, and tax advice.  (4) All
other fees consist of fees billed for all other services.  Audit Committees
Pre-Approval Practice  The
Company does not have an audit committee at this time.Theboard of directors currently performs the function of an audit committee.
 Section 10A (i) of the Securities Exchange Act of 1934, as amended,
prohibits the Companys auditors from performing audit services for the





Company as well as any services not considered to be audit
services unless such services are pre-approved by the audit committee or, in
cases where no such committee exists, by the board of directors (in lieu of an
audit committee) or unless the services meet certain de minimis standards.





PART
IV   ITEM
15 EXHIBITS
AND FINANCIAL STATEMENT SCHEDULES  Exhibits  The following
exhibits are included as part of this report:  Exhibit
No.

Description3.1

Articles of
Incorporation of Registrant (1)3.2

By-Laws of
Registrant (1)3.3

Certificate of
Amendment to Articles of Incorporation3.3

Amendment to
Bylaws(1)31.1

Rule
13(a)-14(a)/15(d)-14(a) Certification of Principal Financial
Officer31.2

Rule
13(a)-14(a)/15(d)-14(a) Certification of Principal Executive
Officer32.1

Rule 1350
Certification of Principal Financial Officer32.2

Rule 1350
Certification of Chief Executive Officer  Filed
with the Securities and Exchange Commission on June 29, 2007, as an exhibit,
numbered as indicated above, to the Registrants registration statement on the
Registrants Registration Statement on Form SB-2 (file no. 333-144226), which
exhibit is incorporated herein by reference.





SIGNATURES   Pursuant to the
requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.  Date: March
31, 2010 ARTVENTIVE
MEDICAL GROUP, INC.  By /s/
H. James Graham Name: H.
James Graham Title: President   Pursuant to the
requirements of the Securities Exchange Act of 1934, this report has been signed
below by the following persons on behalf of the registrant and in the capacities
and on the dates indicated. Signature
Title
DateH.
James Graham
_______
James
Graham
Principal
Financial Officer and Chairman of the Board of Directors
March 31,
2010/s/
Leon Rudakov
Dr. Leon
Rudakov
Chief Executive
Officer, Chief Technology Officer, Member of the Board of Directors
March 31,
2010